Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Liver Cancer Animal Model at AsiaTIDES

Tuesday, February 26, 2019 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

GAITHERSBURG, Md., Feb. 25, 2019 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and

development of RNAi therapeutics against cancer and fibrotic diseases, today announced that the Company will present preclinical data from the use of its RNAi technology program in a liver cancer mouse model at AsiaTIDES: Ogligonucleotide & Peptide
Therapeutics taking place in Tokyo, Japan on February 28 - March 1, 2019.

Presentation Title: siRNA Delivery is Still the Key to Therapeutic SuccessSpeaker: David Evans, PhD., Co-Founder and Chief Scientific Officer of SirnaomicsPresentation Track: Oligonucleotide Date & Time: February 28, 12 pm Tokyo Time

Dr. Evans will present an overview of Sirnaomics' differentiated RNAi technology platform that leverages a proprietary polypeptide nanoparticle (PNP) drug delivery system, as well as a robust clinical pipeline of RNAi therapeutics spanning oncology and anti-fibrosis indications. He will highlight the Company's immuno-oncology data showing STP705 augmentation of immune checkpoint inhibitors (anti-PDL1) in a mouse hepatocellular carcinoma (HCC) model.

About Sirnaomics, Inc.Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.

CONTACT:

Sirnaomics, Inc. Michael Molyneaux MD MBA Chief Medical Officermichaelmolyneaux@sirnaomics.com 

ICR Healthcare Investors:Stephanie CarringtonTel: +1 646 277 1282 Email: Stephanie.Carrington@icrinc.com

Media: James Heins Tel: +1 203 682 8251Email: James.Heins@icrinc.com

 

Cision View original content:http://www.prnewswire.com/news-releases/sirnaomics-to-present-data-demonstrating-stp705-augmentation-of-immune-checkpoint-inhibitors-in-liver-cancer-animal-model-at-asiatides-300801533.html

SOURCE Sirnaomics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store